Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Interleukin-6 as a key player in systemic inflammation and joint destruction.
Targeting IL-6R in both animal models of arthritis and in rheumatoid arthritis patients with a humanized anti IL- 6R monoclonal antibody (tocilizumab) effectively controls local and systemic inflammatory manifestations and blocks cartilage and bone destruction. Expand
Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.
- P. Emery, R. V. van Vollenhoven, +9 authors S. Steinfeld
- Annals of the rheumatic diseases
- 1 April 2009
A cross-sectional comparison of patients with RA in 15 different countries revealed great variation in the drug management, including the delay in starting a disease-modifying antirheumatic drug (DMARD) ranging from 12 months, use of methotrexate, and disease activity scores varied. Expand
Standardising joint assessment in rheumatoid arthritis
The results highlight the extent of variation in clinical assessment of rheumatoid arthritis and show the advantages of training, which leads to increased sensitivity of measurement. Expand
Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study
Oral methotrexate 15 mg weekly showed no significant benefit, but limitations in the trial design and the high rate of response in the placebo group meant that a treatment effect could not be excluded and can inform design of future trials in CIDP. Expand
Smokers and non smokers with rheumatoid arthritis have similar clinical status: data from the multinational QUEST-RA database.
- A. Naranjo, S. Toloza, +30 authors T. Sokka
- Clinical and experimental rheumatology
- 1 November 2010
RA patients who had ever smoked were more likely to have RF and nodules, but values for other clinical status measures were similar in all smoking categories (never smoked, current smokers and former smokers). Expand
Treatment of Rheumatoid Arthritis with Single Dose or Weekly Pulses of Chimaeric Anti‐CD4 Monoclonal Antibody
- E. Choy, I. Chikanza, G. Kingsley, V. Corrigall, G. Panayi
- Scandinavian journal of immunology
- 1 August 1992
It may be concluded that the therapeutic efficacy of anti‐CD4 therapy is not direetly related to CD4 T‐cell lymphopenia. Expand
A randomised, double-blind, placebo-controlled trial of a recombinant version of human α-fetoprotein (MM-093) in patients with active rheumatoid arthritis
- L. Pollard, J. Murray, M. Moody, E. Stewart, E. Choy
- Annals of the rheumatic diseases
- 17 November 2006
Evidence of efficacy was observed in the first randomised, controlled trial of MM-093, a recombinant version of human AFP, in patients with RA, suggesting that MM- 093 may have therapeutic potential in RA. Expand
SEROLOGICAL EFFECTS OF REPEATED DOSES OF AN ENGINEERED HUMAN ANTI-TNF-ALPHA - ANTIBODY, CDP571, IN PATIENTS WITH RHEUMATOID-ARTHRITIS (RA)
THU0199 Tofacitinib, An Oral Janus Kinase Inhibitor, in The Treatment of Rheumatoid Arthritis: Changes in Lymphocytes and Lymphocyte Subset Counts and Reversibility after Up To 8 Years of Tofacitinib…
Tofacitinib treatment resulted in a transient increase in ALC at Month 1, followed by a gradual decline to stabilise below baseline levels by ∼4 years, and reversibility is observed following ST and LT dosing. Expand
Polymorphisms of the FCRL 3 gene in a Spanish population of systemic lupus erythematosus patients
SIR, Increasingly patients are able to access their Rheumatology Department via nurse-led Rheumatology helplines and, due to the over-booking of our clinics and the long distances patients have to… Expand